Stock Ticker

  • Loading stock data...

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) focus on HClO acid based therapeutics

Boston, MA 06/07/2013 (wallstreetpr) – Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) in the previous trading session closed at $3.34 after going down by $0.19 (-5.38%) which closed at $3.53 in the previous trading session of Wednesday. The stock opened its day at $3.33 and hit the day’s low at $3.11 and the day’s high at $3.61. The volume in the previous trading session was close to 0.139 million which was lower than the average volume of 0.143 million shares measured over 1 month period. The relative volume of the stock is 0.94 which is the ratio of current volume and the average volume of the three months. The short float on the total floated shares is about 5.43% while the short ratio is about 2.16. The beta of the stock is about 2.01 which imply that the asset is moving in the same direction as the index but more than the movement of benchmark.

Oculus Innovative Sciences have today announced that the company has engaged itself into the two key arrangements that establish supply and licences as well as services with its totally owned subsidiary that is Ruthigen, Inc. that is focused on commercialization, development and discovery of pharmaceutical HClO acid based therapeutics. The company is also expecting to enter into the third agreement that governs other terms of their business relationship. Ruthigen’s initial public offering closing date is expected to be the effective dates of all the three agreements. Oculus Innovative Sciences is a health care company which is based on the production of devices, drugs and nutritional products.

Published by Nicholas Maithya

Nicholas is a Financial Analyst by profession, who enjoys writing about investments, technological developments, business, economics and other financial topics at various financial publications. Join him here on Wallstreetpr.com as he endeavors to deliver to you the latest breaking news on the above mentioned fronts. Contact him by email at [email protected] or follow Nicholas Kitonyi @nmaithyak on Twitter.

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts